Cutaneous Oncology News

Patients that experience cutaneous immune-related adverse events after immune checkpoint inhibitor treatment are more likely to survive their melanoma diagnosis, according to a study.

While the adoption of immunotherapies and targeted systemic therapies for the treatment of melanoma has increased overall survival in patients, it has also significantly increased health care costs, according to a study.

Findings from a nationwide, population-based cohort study revealed that the current staging system used for melanoma does not represent accurate recurrence and mortality.

Single-cell RNA-sequencing and spatial transcriptomics may be able to identify tumor-specific keratinocyte subpopulations that mark aggressive squamous cell carcinoma in at-risk patients, according to a review.

Chronic immune-associated adverse events appeared common after treatment with adjuvant anti-PD-1 therapy among patients with melanoma, according to study results published in JAMA Network Open.

According to the American Cancer Society, more than 97,000 new melanomas will be diagnosed in the United States in 2023, which will result in upward of 7,900 deaths.

Patients diagnosed with melanoma during the COVID-19 pandemic in 2020 faced a higher likelihood of having thicker, more advanced and more ulcerated tumors, although the impact on survival is still unknown, according to a study.

Asian patients are often diagnosed with mycosis fungoides at a younger age compared with other races and therefore may have higher overall survival rates, according to a study.

The combination of ipilimumab and nivolumab extended PFS compared with ipilimumab alone as second-line therapy for patients with advanced melanoma resistant to PD-1 inhibitors, according to study results published in Nature Medicine.

Patients with Merkel cell carcinoma may have better survival outcomes when treated with Mohs micrographic surgery compared with wide local excision, according to a study.